Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). (Q44189698)
Jump to navigation
Jump to search
scientific article published on 22 August 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). |
scientific article published on 22 August 2002 |
Statements
1 reference
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). (English)
1 reference
1 reference
Urban J Scheuring
1 reference
Heike Pfeifer
1 reference
Barbara Wassmann
1 reference
Patrick Bruck
1 reference
Johannes Atta
1 reference
Eduard K Petershofen
1 reference
Brigitte Gehrke
1 reference
Harald Gschaidmeier
1 reference
Dieter Hoelzer
1 reference
22 August 2002
1 reference
Identifiers
1 reference